Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alcon Inc. Ordinary Shares (NY:ALC)

81.54 -8.58 (-9.52%)
Streaming Delayed Price Updated: 11:32 AM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alcon Inc. Ordinary Shares

< Previous 1 2 3 4 5 Next >
Alcon Cites Tariffs And Soft Market In Lowered Sales Outlook, Shares Fall
Alcon cut its 2025 outlook citing higher tariffs, with Q2 sales missing estimates. Earnings topped forecasts, led by strong vision care demand. 
Via Benzinga
Topics World Trade
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
What Analysts Are Saying About Alcon Stock
 
Via Benzinga
An Overview of Alcon's Earnings
 
Via Benzinga
Alcon Earnings Preview
 
Via Benzinga
Earnings Scheduled For February 25, 2025
 
Via Benzinga
Earnings Scheduled For November 12, 2024
 
Via Benzinga
Alcon Analysts Increase Their Forecasts After Q2 Results
 
Via Benzinga
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
These stocks are moving in today's after hours session
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
Tech Stocks Drop, Palantir Plunges Over 8%: What's Moving Markets Tuesday?
Tech stocks pulled back on Tuesday as the absence of fresh bullish catalysts prompted investors to take profits after the recent months-long rally. 
Via Benzinga
Earnings Scheduled For August 19, 2025
 
Via Benzinga
Predicting the Next Rule Breaker Buyout
Having a stock you own get acquired at a premium feels good at first, but what about the long-term gains that will be left behind when your chips are off the table? 
Via The Motley Fool
Topics Artificial Intelligence
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition
Alcon will acquire STAAR Surgical for $1.5 billion to expand surgical vision correction options for high myopia, including EVO ICL lenses. 
Via Benzinga
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production. 
Via Benzinga
Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
American Eagle, Cisco Systems And 3 Stocks To Watch Heading Into Wednesday
 
Via Benzinga
3 Stocks Upping Dividends & 1 With A 10% Special Dividend Yield
Via MarketBeat
Alcon Eyes Surgical Edge With LENSAR Buyout: Details
Alcon is set to acquire LENSAR Inc. in a $356 million deal. This acquisition includes LENSAR's advanced cataract laser technologies, boosting Alcon's offerings in femtosecond laser-assisted cataract... 
Via Benzinga
Apple To $253? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
Earnings Scheduled For May 13, 2025
 
Via Benzinga
Tesla To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
ALC Stock Earnings: Alcon Beats EPS, Misses Revenue for Q2 2024
ALC stock results show that Alcon beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
S&P 500, Nasdaq Extend Gains For 8th Consecutive Session: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone
 
Via Benzinga
Topics Stocks
Lowe's, Palo Alto Networks And 3 Stocks To Watch Heading Into Tuesday
 
Via Benzinga
Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED
Japan’s Eisai Pharma formed a collaboration with SEED, a Pennsylvania biotech, to develop molecular glues for targeted protein degradation of disease-causing proteins. SEED is eligible to receive up to... 
Via Talk Markets
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.